Figure 3 | Scientific Reports

Figure 3

From: Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway

Figure 3

Proliferation of tumor cells in response to AO-I, paclitaxel or LPS.

(A). Cell viabilty (%) of SKOV3 and A2780 cells treated with LPS (0.1 emsp14;μg/ml) alone or combined with AO-1 for 72 hours (n = 3); (B). Cell viabilty (%) of SKOV3 and A2780 cells treated with paclitaxel alone or combined with AO-1(100 μmol/L) or with LPS (0.1 μg/ml) (n = 3).

Back to article page